Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

HER2-positive Breast Cancer 1HER2 Overexpression 1

Interventions

pembrolizumab 1282Specimen Handling 927Carboplatin 836Magnetic Resonance Spectroscopy 834Cyclophosphamide 807Cisplatin 735Nivolumab 680Paclitaxel 635Radiotherapy 617Gemcitabine 580Biopsy 559Bevacizumab 485Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 361Fluorouracil 357atezolizumab 350durvalumab 340Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 319Blood Specimen Collection 317Standard of Care 311Pemetrexed 307Ipilimumab 303Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Isovaleryl-CoA Dehydrogenase × 1 year × Clear all
NCT07281001 2025-12-15

Traderrus

Blokhin's Russian Cancer Research Center

Phase NA Recruiting
60 enrolled
Breast

HER2-positive Breast Cancer

NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡